Literature DB >> 1348000

A comparison of the effect of salmeterol and salbutamol in normal subjects.

J Spring1, J Clague, P W Ind.   

Abstract

1. The effects of salmeterol hydroxynaphthoate (50 micrograms, 8.3 x 10(-8) M) and salbutamol (200 micrograms, 3.5 x 10(-7) M) on sGaw were compared in a double-blind, placebo-controlled, randomised study in 10 normal subjects. 2. SGaw increased by 29% (14-43) (mean (CI)), 5 min after salmeterol and by 35% (19-51) at 15 min compared with an increase of 32% (14-51) and 37% (10-63) after salbutamol and 4% (-3-11) and 8% (0-16) after placebo. 3. The mean area under the sGaw-time curve (AUC480) after salmeterol inhalation was 22,500 kPa-1 (10,100-39,500) compared with 14100 kPa-1 (8020-24,500) after salbutamol and 5300 kPa-1 (1500-10,400) after placebo. 4. Salmeterol produced a significantly prolonged bronchodilator effect compared with salbutamol in normals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348000      PMCID: PMC1381298          DOI: 10.1111/j.1365-2125.1992.tb04015.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.

Authors:  A Ullman; N Svedmyr
Journal:  Thorax       Date:  1988-09       Impact factor: 9.139

2.  The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

Authors:  I A Choonara; R G Malia; B P Haynes; C R Hay; S Cholerton; A M Breckenridge; F E Preston; B K Park
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

3.  Changes in specific airways conductance and forced expiratory volume in one second after a bronchodilator in normal subjects and patients with airways obstruction.

Authors:  C Skinner; K N Palmer
Journal:  Thorax       Date:  1974-09       Impact factor: 9.139

4.  A new method for computer-assisted determination of airways resistance.

Authors:  P J Chowienczyk; P J Rees; J Payne; T J Clark
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-03

5.  Quantitative assessment of bronchial beta-adrenoceptor blockade in man.

Authors:  H R Gribbin; C J Baldwin; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

6.  Autoradiographic visualization of beta-adrenoceptor subtypes in human lung.

Authors:  J R Carstairs; A J Nimmo; P J Barnes
Journal:  Am Rev Respir Dis       Date:  1985-09

7.  Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist.

Authors:  M F Fitzpatrick; T Mackay; H Driver; N J Douglas
Journal:  BMJ       Date:  1990-12-15

8.  Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis.

Authors:  A Ullman; J Hedner; N Svedmyr
Journal:  Am Rev Respir Dis       Date:  1990-09

Review 9.  The pharmacology of salmeterol.

Authors:  M Johnson
Journal:  Lung       Date:  1990       Impact factor: 2.584

  9 in total
  1 in total

1.  Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials.

Authors:  Virginia Norris; Claire Ambery
Journal:  Drugs R D       Date:  2014-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.